Claims for Patent: 8,232,383

Summary for Patent: 8,232,383

Title:	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
Abstract:	The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
Inventor(s):	McSwiggen; James (Boulder, CO), Beigelman; Leonid (Longmont, CO)
Assignee:	Sirna Therapeutics, Inc. (San Francisco, CA)
Application Number:	12/105,010
Patent Claims:	1. A chemically modified nucleic acid molecule that mediates RNA interference, wherein: (a) the nucleic acid molecule comprises a sense strand and a separate antisense strand; (b) each strand of the nucleic acid molecule is independently 18 to 24 nucleotides in length; (c) the antisense strand is complementary to a target RNA sequence; (d) the sense strand includes a terminal cap moiety at its 5'- and 3'-ends; and (e) all pyrimidine nucleotides of the sense strand and the antisense strand are chemically modified with 2'-deoxy, 2'-O-methyl, or 2'-deoxy-2'-fluoro nucleotides. 2. The nucleic acid of claim 1, wherein all pyrimidine nucleotides present in the sense strand are 2'-O-methyl pyrimidine nucleotides. 3. The nucleic acid of claim 1, wherein all pyrimidine nucleotides present in the sense strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides. 4. The nucleic acid molecule of claim 1, wherein all pyrimidine nucleotides present in the antisense strand are 2'-O-methyl pyrimidine nucleotides. 5. The nucleic acid molecule of claim 1, wherein all pyrimidine nucleotides present in the antisense strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides. 6. The nucleic acid molecule of claim 1, wherein the terminal cap moiety is an inverted deoxy abasic moiety. 7. The nucleic acid molecule of claim 1, comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 phosphorothioate internucleotide linkages. 8. A composition comprising the nucleic acid molecule of claim 1, in a pharmaceutically acceptable carrier or diluent. 9. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises one or more ribonucleotides.